81673444) and the Postdoctoral Science Foundation of Anhui Province (No
Hyperhomocysteinemia and cardiovascular diseases
Therapies, including finerenone, incretin-based therapy, SGLT-2 inhibitors, and emerging neuroprotective treatments may met the need for reducing NPDR progression
Wallner M, Kolesnik E, Ablasser K, Khafaga M, Wakula P, Ljubojevic S, Thon-Gutschi EM, Sourij H, Kapl M, Edmunds NJ, Kuzmiski JB, Griffith DA, Knez I, Pieske B, von Lewinski D (2015) Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium
These include improving clinical markers in neurodegenerative diseases, treating congestive heart failure, lowering cholesterol and blood sugar, minimising bone loss, and improving cognitive performance [4]
Its considered very safe when administered by trained professionals